- Home
- CANF vs AEI Comparison
CANF vs AEI Comparison
Compare CANF & AEI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CANF
- AEI
- Stock Information
- Founded
- CANF 1994
- AEI 2014
- Country
- CANF Israel
- AEI United States
- Employees
- CANF N/A
- AEI N/A
- Industry
- CANF Biotechnology: Pharmaceutical Preparations
- AEI Building operators
- Sector
- CANF Health Care
- AEI Real Estate
- Exchange
- CANF Nasdaq
- AEI Nasdaq
- Market Cap
- CANF 13.5M
- AEI 10.9M
- IPO Year
- CANF N/A
- AEI N/A
- Fundamental
- Price
- CANF $1.03
- AEI $1.07
- Analyst Decision
- CANF Strong Buy
- AEI
- Analyst Count
- CANF 2
- AEI 0
- Target Price
- CANF $14.00
- AEI N/A
- AVG Volume (30 Days)
- CANF 141.2K
- AEI 120.5K
- Earning Date
- CANF 08-29-2025
- AEI 08-12-2025
- Dividend Yield
- CANF N/A
- AEI N/A
- EPS Growth
- CANF N/A
- AEI N/A
- EPS
- CANF N/A
- AEI N/A
- Revenue
- CANF $674,000.00
- AEI $16,097,995.00
- Revenue This Year
- CANF $461.72
- AEI N/A
- Revenue Next Year
- CANF N/A
- AEI N/A
- P/E Ratio
- CANF N/A
- AEI N/A
- Revenue Growth
- CANF N/A
- AEI N/A
- 52 Week Low
- CANF $0.98
- AEI $0.70
- 52 Week High
- CANF $4.69
- AEI $2.61
- Technical
- Relative Strength Index (RSI)
- CANF 41.84
- AEI 55.44
- Support Level
- CANF $1.00
- AEI $1.05
- Resistance Level
- CANF $1.05
- AEI $1.15
- Average True Range (ATR)
- CANF 0.03
- AEI 0.10
- MACD
- CANF 0.00
- AEI 0.01
- Stochastic Oscillator
- CANF 40.00
- AEI 38.67
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).
About AEI Alset Inc. (TX)
Alset Inc is a diversified holding company engaged through its subsidiaries in the development of EHome communities and other real estate, financial services, digital transformation technologies, biohealth activities, and consumer products with operations in the United States, Singapore, Hong Kong, Australia, and South Korea. The Company operates in four business segments: real estate, digital transformation technology, Biohealth, and other business activities, and it derives a majority of its revenue from the Real Estate segment.